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Abstract: 
Objectives: The extent to which gastrocnemius muscle and Achilles tendon properties 
contribute to the impaired walking endurance of claudicants is not known. Methods: 
Ultrasound images quantified muscle architecture of the lateral and medial gastrocnemius 
(GL and GM) and were combined with dynamometry during plantarflexor contractions to 
calculate tendon stress, strain, stiffness, the Young modulus, and hysteresis. Key parameters 
were entered into multiple regression models to explain walking endurance. Results: Worse 
disease severity was significantly associated with longer fascicle: tendon length ratios (GL R 
= -0.789 and GM R = -0.828) and increased tendon hysteresis (R = -0.740). Walking 
endurance could be explained by GL and GM pennation angle, maximum tendon force, 
tendon hysteresis, and disease severity (R
2 
= ~0.6). Conclusions: Peripheral arterial disease
was associated with functionally important changes in muscle and tendon properties, 
including the utilization of stored elastic energy. Interventions known to target these 
characteristics should be adopted as a means to improve walking endurance. 
Keywords: Efficiency; hysteresis; endurance; intermittent claudication; gastrocnemius 
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Introduction 
Peripheral arterial disease with intermittent claudication (PAD-IC) primarily affects older 
adults, and prevalence increases with advancing age
1
. The disease can be physically limiting 
by impacting adversely on individual quality of life, walking endurance, functional ability, 
and independence
2-4
. The calf muscle is frequently reported as a site of claudication pain,
5
 
and there is evidence of plantarflexor dysfunction during level walking
6,7
. However, the 
contribution of musculoskeletal factors, either individually or in combination with one 
another, to the functional and quality of life limitations associated with PAD-IC are unclear. 
 
The functional properties of muscle depend on overall size and fascicle arrangement
8
. 
Muscles required to generate large forces develop highly pennate architecture (the angle 
between fascicles and the muscle’s line of action) with short fascicles, while those that 
require large excursions/high velocity develop long fascicles
9
. Long fascicles relative to 
tendon length also have the advantage of reduced relative fascicle velocity for any given 
movement
9
 and decreased energy cost for the same mechanical work
10
. Architectural 
characteristics adapt to chronic loading, unloading, and aging
11
. Those with PAD-IC are 
typically older individuals
1
 who are less physically active than their healthy counterparts
12
 
and have the added burden of reduced blood supply to working muscles. Consequently, it is 
expected that the architecture of claudicant muscles may differ from healthy controls, 
impacting on muscle function and energy requirements. 
 
Muscle work is transmitted to the skeleton by the tendon, which deforms, stretching and 
recoiling, during movement. Consequently, tendon properties can modulate the outcome of 
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muscle contraction by impacting muscle length, maximum muscle force production, and the 
rate of force development
13
. Tendons store elastic energy when stretched, some of which is 
lost as heat (defined as hysteresis), but the remainder is recovered during recoil to contribute 
to the next shortening task. This reduces the metabolic energy required from the muscle 
during shortening (e.g., propulsion in walking), which improves movement efficiency
14
. 
 
Tendon properties have been shown to deteriorate with increasing age,
15
 and these adverse 
changes may be linked to reduced blood supply
16
. Given the increasing prevalence of PAD-
IC with advancing age
1
 combined with disease-induced reductions in blood supply, it is 
possible that the tendons of claudicants undergo significant deterioration compared to healthy 
counterparts. The reduced levels of physical activity associated with PAD-IC
3
 mean that 
claudicant tendons may experience further deterioration with disuse
17
. In combination, it 
seems likely that the tendons of claudicants would be smaller, weaker, and have greater 
hysteresis (lost elastic energy) than those of healthy individuals. 
 
The purpose of this study was to determine: (1) whether PAD-IC causes in vivo alterations in 
gastrocnemius muscle architecture and the material and mechanical properties of the Achilles 
tendon and (2) whether these parameters influence walking endurance. This was achieved by: 
(1) exploring relationships between muscle-tendon characteristics and disease severity [ankle 
brachial pressure index (ABPI)] and drawing comparisons to a healthy control group of older 
adults, and (2) multiple regression modelling of muscle-tendon characteristics to explain 
initial and absolute claudication walking distances. It was hypothesised that PAD-IC would 
induce changes comparable to disuse and aging: shorter relative fascicle lengths 
(fascicle:tendon length ratio), reduced pennation angles, tendon stiffness and the Young 
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modulus, and greater hysteresis and peak strain. Our second hypothesis was that these 
muscle-tendon parameters would be able to explain a large portion of walking endurance 
with the aforementioned changes having detrimental effects. 
 
Methods 
Participants 
Ethical approval was granted by the NHS Research Ethics Committee (REC reference: 
11/YH/0335). A total of 22 participants were recruited, consisting of 12 claudicants (7 
unilateral and 5 bilateral) and 10 healthy controls (Table 1). Men and women aged 55-80 
years and diagnosed with Rutherford Grade 1 chronic limb ischemia
18
 with a narrowing of 
the superficial femoral artery and not currently under any form of treatment nor previously 
enrolled in an exercise intervention for PAD-IC were recruited via consultant referral from a 
local outpatient vascular clinic. Healthy older adults were recruited from the local community 
as a control group. Participants were excluded if they had a severe or acute cardiovascular, 
musculoskeletal, neurological, or pulmonary illness; a history of stroke, myocardial infarction 
or life-limiting diseases, such as cancer; a previous hip or knee replacement or observable 
gait abnormalities. 
 
Experimental protocol 
Disease severity was determined according to the ABPI. Systolic blood pressure was 
measured in the posterior tibial and dorsalis pedis arteries of each leg and the brachial 
pressure of both arms, separately, using a sphygmomanometer cuff and a hand held Doppler 
instrument (Parks Medical Electronics Inc, Oregon, USA). ABPI measures for both lower 
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limbs were taken pre- and post- a standardized exercise protocol performed on a motorized  
treadmill (5 minutes, 2.5 km/h, 10% incline). Post-exercise ABPI was used to categorize  
participant limbs and assess disease severity. In accordance with standard protocol, the ABPI  
for both legs was then calculated as the higher of the 2 leg artery pressures normalized to the  
higher brachial pressure of the 2 arms
5
. Symptomatic limbs (ABPI <0.9) for all claudicants  
were then categorized into those with low disease severity (high ABPI, N=7, providing 8  
limbs for analysis) and high disease severity (low ABPI, N=7, providing 8 limbs for analysis)  
groups, by splitting them at the median ABPI (0.59). For the sake of brevity, these groups  
will be referred to as ‘low ABPI’ and ‘high ABPI’ throughout. This threshold does not  
necessarily reflect a clinically important marker of vascular function but allows an  
exploration of whether disease severity-induced changes in muscle and tendon properties  
were detectable between participants within the ABPI range of our sample. The non- 
claudicating limb of the unilateral patients was subsequently identified to represent the  
‘asymptomatic-limb’ group (N=7, providing 7 limbs for analysis). Control participants also  
undertook the exercise protocol to determine ABPI values and confirm the absence of disease  
(N=10, providing 10 limbs for analysis).  
  
Walking endurance  
A modified 6-minute walk test on level ground was performed and was combined with the  
ACSM claudication pain rating scale
19
 to allow those who were able to walk longer than 6- 
minutes to do so
20
. Patients walked continuously along a 10m walkway at a self-selected pace  
and reported the level and position of any pain every 20m. Initial claudication distance (ICD)  
was classed as level 1 on the pain scale and signified the onset of pain. Absolute claudication  
distance (ACD) was classed as level 4 on the pain scale and signified maximal pain.  
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Muscle architecture measures  
Participants lay prone on a plinth with their ankle plantarflexed and supported on the bed  
with the musculature relaxed. B-mode ultrasound imaging (50-mm probe length, MyLab50 x- 
vision, Esaote Biomedica, Genoa, Italy) was used to visualize resting muscle architecture of  
the GL and GM in the sagittal plane at 50% of muscle length. Fascicle length, pennation  
angle, and muscle thickness were measured from 3 separately exported images using ImageJ  
(version 1.44, NIH, USA), with the average taken forward for further analysis. For each  
image, the length of 1 fascicle with its insertion angle onto the deep aponeurosis and 1  
instance of muscle thickness were measured. In cases where the fascicle length exceeded the  
ultrasound viewing window, the aponeurosis was extrapolated to allow for fascicle length  
measurements to be estimated
21
.   
  
Ultrasound imaging was also used to identify the proximal and distal ends of the muscle, and  
the calcaneal insertion of the Achilles tendon. A tape measure was then used to measure  
muscle-tendon unit (MTU) and muscle lengths. Data were analyzed in absolute terms and  
after scaling to individual anthropometric dimensions.  
  
Measures and calculations for tendon properties  
Calculating Achilles tendon force  
The gastrocnemius contribution to Achilles tendon force during isometric plantarflexion  
maximal voluntary contractions (MVCs) was calculated using equations (1) and (2):  
Page 8 of 32
John Wiley & Sons, Inc.
Muscle & Nerve
This article is protected by copyright. All rights reserved.
 8 
 
8 
 
1) 		 =

	

  
where AT force is Achilles tendon force, GS moment is the gastrocnemius contribution to  
joint moment, calculated through equation (2), and MA is Achilles tendon moment arm  
length.  
2) 		 = 			 + 			– 	 	  
where each component is detailed below.  
  
Joint moment was recorded while participants performed 3 ramped plantarflexion MVCs  
lasting approximately 5 seconds and then returned to rest across the same time period on an  
isokinetic dynamometer (Biodex System 3, Biodex Medical Systems Inc, New York, USA).  
Participants were seated in a standardized upright position: hip flexed (85°), knee extended  
(0°), and ankle dorsiflexed (maximum dorsiflexion within individual range of motion).  
Practice trials were performed prior to testing, and visual feedback was provided to ensure a  
consistent rate of rise in plantarflexor moment during each test. Adequate rest was provided  
between trials (~1 min), and the trial with the highest MVC was selected for further analysis.   
  
Antagonist co-activation during the plantarflexion MVC was assessed using surface EMG of  
the tibialis anterior (Telemyo 2400T, Noraxon, Arizona, USA). The dorsiflexion EMG- 
moment relationship was constructed from 4 dorsiflexion contractions of increasing intensity.  
The tibialis anterior EMG at each stage of the ramped plantarflexion trials was then  
substituted into this relationship to predict antagonist dorsiflexor moment
22
. The soleus  
contribution to plantarflexor moment was quantified during additional plantarflexion  
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contractions lasting approximately 3 seconds with the knee flexed to 90°, where the  
gastrocnemius muscles were slack and did not contribute to the joint moment
23
. The soleus  
EMG-moment relationship across the 2 joint configurations [knee extended (0°) and knee  
flexed (90°)] was used to correct activation differences (equation 3):  
3)  		!	0° =
$%&		'	()°∗	$%&	+
	'	)°
$%&	+
	'	()°
  
  
Achilles tendon moment arm (MA) was calculated using the tendon excursion method
23,24
  
and ultrasound imaging to quantify linear myotendinous junction displacement.  
  
Achilles tendon dimensions and elongation  
For the purposes of calculating tendon properties, Achilles tendon resting length was  
measured from the proximal origin at the myotendinous junction of medial gastrocnemius to  
the distal insertion at the calcaneus while the ankle was in maximum dorsiflexion prior to  
plantarflexion contractions (participant positioning described above). These locations were  
identified using ultrasound imaging, and the length was measured using a tape. Free tendon  
cross-sectional area (CSA) was measured at 1, 2, and 3 cm proximal to the insertion onto the  
calcaneus using axial-plane ultrasound imaging
23
 and was analyzed using ImageJ. The  
average of all 3 sites was used for further calculations.  
  
The ultrasound probe was aligned with the distal myotendinous junction of the medial  
gastrocnemius and the Achilles tendon in the sagittal plane and was securely fixed to the skin  
with an echo-absorptive marker within the viewing window to allow for correction of any  
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artifacts caused by probe movement
25
. Ultrasound videos were synchronized with 
plantarflexor moments during MVCs lasting approximately 5 seconds (described above) to 
track myotendinous junction displacement. Images were digitized to measure tendon 
elongation at each 10% of peak tendon force using ImageJ.  
 
Tendon stiffness, the Young modulus, and tendon hysteresis 
Force-elongation curves were constructed for the loading (increasing contraction) and 
unloading (relaxation) phases for all participants, and each was fitted with a second order 
polynomial equation between 10-100% of tendon force (for all R
2
<.95). The following 
parameters were calculated for each participant at their individual MVC: tendon stiffness, 
strain, stress, and the Young modulus. Stiffness was calculated as the gradient of the force-
elongation curve by differentiating the equation at each individual’s MVC. Tendon strain was 
calculated by normalizing elongation to resting length. Tendon stress was calculated by 
normalizing tendon force to CSA. The tendon Young modulus was calculated as tendon 
stiffness multiplied by the ratio of tendon length to CSA
13,23,26
. Energy stored in the tendon 
was calculated as the area beneath the whole of the loading curve, and energy released was 
calculated as the area beneath the unloading curve by integrating a second second order 
polynomial equation describing the respective force-elongation curves between 0-100% of 
tendon force. Hysteresis was calculated as the difference between the energy stored and 
energy released and normalized as a percentage of the energy stored. 
 
Statistical analysis 
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A Pearson partial product-moment correlation was performed to assess relationships between 
disease severity (as assessed by ABPI and controlled for the influence of age), walking 
endurance (as assessed by ICD and ACD), and gastrocnemius architecture parameters and all 
Achilles tendon parameters in the symptomatic limbs only. Data were examined for normal 
distribution and outliers by visual inspection of histogram and box-plots. A one-way 
ANOVA was performed to compare differences in muscle-tendon parameters between the 
healthy controls, asymptomatic-limb group, and high and low ABPI groups. Sidak post-hoc 
tests were applied when appropriate. Where non-parametric variables were identified, 
independent samples Kruskal-Wallis tests were performed with subsequent Mann-Whitney U 
tests applied where appropriate. 
 
To assess which architectural parameters and Achilles tendon properties were most important 
to explain variations in walking endurance (as measured by ICD and ACD), a backwards 
step-wise regression was performed on the symptomatic limbs (N=16) to avoid the 
suppressor effect typically associated with forwards step-wise regression models
27
. Key 
variables included in the analysis were GL and GM fascicle:tendon lengths, pennation angle 
and muscle thickness; tendon force, strain, stiffness, and mechanical hysteresis; and ABPI. 
 
For all statistical tests, significance was accepted at P≤.05, and trends were accepted at 
P<.10. Where appropriate, effect size (ES) and study power is also stated. For correlation and 
regression analyses, a moderate relationship was accepted as R=.40 – .59, a strong 
relationship as R=.60 – .79, and a very strong relationship as R=.80 – 1.0
28
. Since low ABPI 
values indicate high disease severity, a positive relationship signifies a decrease in the 
respective parameter with increasing disease severity. 
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Results 
No significant differences were found between any groups for age (P=0.414), height 
(P=0.345), mass (P=0.543), or BMI (P=0.796) (Table 1). No significant differences existed 
between low ABPI, high ABPI, or unilateral (asymptomatic-limb) groups in ICD (P=0.197) 
or ACD (p=.321). Between-group differences in ABPI were consistent with disease 
presentation. 
 
Correlation analysis 
Increasing disease severity was significantly correlated with longer GL and GM fascicle: 
tendon lengths, shorter tendons, greater tendon strain, and greater tendon hysteresis (Figure 
1). Poorer walking endurance, as measured by ICD, was associated with longer GL and GM 
fascicle: tendon lengths, greater GM pennation angle, and trends towards higher tendon strain 
and hysteresis. Poorer maximum walking endurance, as measured by ACD, was associated 
with increased GL and GM pennation angle. Individual R- and P-values are listed in Tables 2 
and 3 for all correlations. Disease severity was not associated with ICD (R = 0.215, P = 
0.441) or ACD (R = 0.161, P = 0.566). 
 
Between-group comparisons 
Several differences were detected between groups in absolute and relative muscle-tendon 
dimensions (Table 4). In the GL, relative fascicle: tendon length was smaller in the high 
ABPI group compared to the control group (P = 0.027, ES = 0.37, power = 0.40). In the GM, 
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the low ABPI (high disease severity) group had longer fascicle lengths compared to controls 
(P = 0.014, ES = 0.55, power = 0.78) and longer fascicle: tendon lengths compared to the 
high ABPI group (P = 0.050, ES = 0.56, power = 0.29).  
 
At individual maximum tendon force, both claudicant groups and the asymptomatic-limb 
group demonstrated reduced Young modulus compared to the control group (P = 0.029 - 
0.100, ES = 0.41 - 0.47, power = 0.50 - 0.65; Table 4). Compared to controls, tendon stiffness 
was lower in the asymptomatic-limb group (P = 0.053, ES = 0.57, power = 0.85; Table 5). 
The low ABPI (high disease severity) had significantly greater mechanical hysteresis 
compared to the high ABPI group (P = 0.004, ES = 0.62, power = 0.88) and showed a trend 
towards increased hysteresis compared to the control group (42%, P = 0.065, ES = 0.49, 
power = 0.65) (Table 5).  
 
No significant differences existed between all groups for MVC (P = 0.631), GS moment (P = 
0.738), moment arm (P = 0.414), or peak tendon force (P = 0.825) (Table 5).  
 
Regression analysis 
Walking distances were not explained by ABPI alone (see correlations above). The inclusion 
of muscle-tendon parameters with ABPI led to significant predictions of both ICD and ACD 
(P = 0.041 and P = 0.037, respectively). Sixty-five percent of the variance in ICD could be 
explained using ABPI, GL and GM pennation angle, tendon force, tendon stiffness, and 
mechanical hysteresis (Table 6). Similarly, ABPI, GL and GM pennation angle, tendon force, 
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and mechanical hysteresis was the strongest combination to predict ACD and could explain  
59% of the variance (Table 7).  
  
Discussion   
This study quantified the fascicle architecture of the gastrocnemii muscles and the  
mechanical and material properties of the Achilles tendon in patients with PAD-IC. In partial  
support of our first hypothesis, associations were found between low ABPI values (increased  
disease severity), relatively longer GL and GM fascicles, and increased tendon mechanical  
hysteresis. These were supported by significant differences between claudicants, particularly  
those with more severe forms of disease, and controls in both architectural parameters and  
tendon properties. The results indicate that these changes in muscle-tendon properties play an  
important role in influencing walking endurance in claudicants and can explain a large  
portion of the variance in walking distances that ABPI alone cannot.   
  
Correlation analysis revealed that both GL and GM fascicle lengths increased while tendon  
length decreased significantly, leading to greater fascicle: tendon length ratios with increasing  
disease severity. Additionally, those with lower ABPI had significantly longer GM fascicle:  
tendon lengths compared to those with higher ABPI (Table 2). These adaptations allow the  
muscle-tendon unit to lengthen and shorten with less relative fascicle, and therefore  
sarcomere, displacement. As a result, the GM MTU in those with low ABPI values appear to  
have adapted in such a way that would facilitate length changes during movement with less  
energy consumption per unit of muscle force
10
. However, the impact of this potential energy  
saving adaptation may be negated by the concomitant increase in mechanical hysteresis,  
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which was 42% greater in those with low ABPI compared to the control group (Figure 1 and 
Table 5). Individuals with more severe forms of PAD-IC and those with limited walking 
endurance are less able to utilize this energy recovery mechanism in the tendon and must 
provide metabolic energy to the muscles to make up the shortfall, thus increasing the energy 
cost of movement. This observation is commensurate with reported reductions in walking 
economy with greater disease severity
29
. Therefore, efforts to improve the recovery and 
utilization of the energy stored in the tendon (by reducing hysteresis) through appropriately 
designed interventions, such as progressive resistance training
26
, may have substantial 
benefits for walking endurance in this population. 
 
The second aim of this study was to elucidate the extent to which gastrocnemius muscle 
architecture and Achilles tendon properties influence walking endurance. ABPI alone could 
not explain variations in walking distances, but when combined with the muscle-tendon 
parameters, significant models that could explain a moderate-large portion of the variance (R
2 
 
= 0.65 and R
2 
= 0.59 for ICD and ACD, respectively) were found. The construct of both 
models with the highest adjusted R
2
 (Tables 6 and 7) has justifiable biomechanical and 
physiological reasoning, and this provides confidence in their validity. We hypothesized that 
greater hysteresis would have a negative impact on walking endurance, which has been 
substantiated. Pennation angle, which was included in both models, can be considered to be 
an index of muscle functional “design”, with lower angles suited to large excursions rather 
than force production
9
. Since pennation angle was predominantly associated with negative 
coefficients in both models containing the fewest parameters and those with the highest 
adjusted R
2
 (Tables 6 and 7), this suggests that muscles with a “design” favouring length 
changes are beneficial to walking endurance. Longer fascicle: tendon length ratios would also 
reflect such a functional design, thus, the exclusion of fascicle: tendon length ratio from the 
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models suggests that pennation angle was adequate to explain this portion of the variance. 
Interestingly, GM pennation with negative coefficients was present in models that could 
explain the most variance and the most efficient models for both ICD and ACD, reinforcing 
the importance of muscle “design” in predicting walking capacity. Finally, tendon force had a 
positive coefficient in both models, indicating that greater muscle strength allowed longer 
walking distances. This may be because greater maximum strength would mean the 
mechanical demands of walking are lower relative to maximum capacity, thus according to 
the size principle
30
, the muscle may rely to a greater extent on the more efficient slow-type 
muscle fibers. It must be acknowledged that the sample size of this study was small for 
typical multiple regression models, which require further exploration and validation. Future 
work should further explore the role of each parameter in explaining walking endurance and 
consider how these variables respond to treatment and the subsequent impact on walking 
endurance. 
 
Interestingly, the tendon properties in the asymptomatic-limb group were more similar to the 
claudicating limbs than the controls. This observation was confirmed by additional pairwise 
t-tests between the symptomatic and asymptomatic limbs of unilateral claudicants that 
revealed no significant differences between limbs. It suggests that either systemic adaptations 
were impacting the asymptomatic limb, in particular the asymptomatic tendon, or disuse 
resulting from reduced physical activity levels led to deterioration in tendon properties. At 
this stage it is not possible to determine which of these mechanisms may be responsible.  
 
This study has some limitations. First, architectural characteristics were measured at a single 
site within the muscle, and muscle architecture may not be homogeneous across the entire 
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muscle. Second, the calculation of tendon force required simplification of the forces acting 
about the joint, but this approach has been validated in numerous previous studies
13,23,26
. 
Specifically, accounting for antagonistic co-activation using the EMG of the TA during 
dorsiflexor contractions likely underestimates the true dorsiflexor co-activation moment
31
. 
Additionally, we assumed that the gastrocnemii did not contribute towards measured 
plantarflexor moment with the knee flexed at 90°, though we were unable to confirm this 
quantitatively. However, it is certain that, at such a short muscle length, the gastrocnemius 
force was substantially reduced compared to longer muscle lengths. There were no between 
group differences in antagonist co-activation, moment-angle relationships
32
, or associations 
with disease severity, therefore we do not believe these assumptions have a confounding 
effect on our data. It must also be acknowledged that our sample was small, which may have 
caused some Type II error. Nonetheless, disease-associated changes were detected, and 
biomechanically and physiologically sound multiple regression models were established, thus 
the sample appeared adequate for the purposes of the study. Future work should seek to 
validate these models in larger and more diverse samples.  
 
This study indicates that improving tendon properties and increasing strength, but without 
increasing pennation angle, would be beneficial for walking endurance. Finding such an 
intervention is not simple, since the majority of exercise interventions that improve strength, 
e.g. resistance training, also increase pennation angle
33
. However, eccentric resistance 
training may provide a viable solution, since it has been shown to improve tendon 
properties
34
 and increase muscle strength while lengthening fascicles but not increasing 
pennation
33
. Previous research on resistance training with claudicants is sparse, with 
conflicting reports of effectiveness
35
. This inconsistency could be due to the use of 
conventional, predominantly concentric resistance training, which may not elicit the optimal 
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adaptations for walking endurance. Future exercise studies should evaluate the effectiveness  
of eccentric resistance training for improving walking endurance of individuals with PAD-IC.  
  
Conclusions  
This study has shown that more severe forms of PAD-IC is associated with muscle  
remodelling towards larger GM fascicle: tendon length ratios and less effective utilization of  
elastic energy stored in the Achilles tendon (increased hysteresis). Importantly, when  
combined with ABPI, tendon hysteresis, architectural parameters of muscle functional  
design, and the muscle’s force producing capacity were able to explain large portions (~65%)  
of walking endurance. These findings suggest that eccentric resistance training of the  
plantarflexor muscles may be a valuable intervention to improve tendon properties, muscle  
function, and ultimately walking endurance.   
  
Abbreviations:  
ABPI – Ankle brachial pressure index  
ACD – Absolute claudication distance  
BMI – Body mass index  
CSA – Cross-sectional area  
ES – Effect size  
GL – Lateral gastrocnemius  
GM – Medial gastrocnemius  
GS – Gastrocnemii (i.e. lateral and medial gastrocnemius combined)  
ICD – Initial claudication distance  
MTU – Muscle-tendon unit  
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MVC – Maximal voluntary contraction 
PAD-IC – Peripheral arterial disease 
TA – Tibialis anterior  
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Figure 1.  Correlations between disease severity (ABPI) and GL and GM fascicle : tendon 
length ratio (a and b respectively) and tendon mechanical hysteresis (c). Average control and 
asymptomatic-limb groups are shown for comparison and are not included in correlation 
analysis 
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Table 1. Participant characteristics. Data are presented as group mean (SD) unless otherwise  
stated. BMI – Body mass index, ABPI – Ankle brachial pressure index. ICD – Initial  
claudication distance. ACD – Absolute claudication distance.   
 
 
Low ABPI High ABPI 
Asymptomatic-
limb 
Healthy 
Control 
# limbs 8 8 7 10 
% Men 77.8 87.5 57.1 40 
Age (years) 64.3 (4.7) 65.5 (8.0) 66.1 (7.5) 61.6 (3.6) 
Height (m) 1.72 (0.07) 1.73 (0.06) 1.69 (0.10) 1.67 (0.09) 
Mass (Kg) 81.1 (15.9) 82.5 (21.5) 82.3 (21.1) 72.3 (10.9) 
BMI (Kg/m
2
) 27.6 (5.3) 27.3 (5.9) 28.5 (4.8) 26.1 (3.7) 
ABPI pre-exercise 
ABPI post-exercise 
0.71 (0.19) 0.89 (0.22) 1.01 (0.16) 1.00 (0.09) 
0.39 (0.17) 0.63 (0.15) 0.90 (0.06) 1.01 (0.15) 
ICD (m) 106.3 (51.0) 123.8 (47.2) 80.0 (16.7) n/a 
ACD (m) 285.0 (141.7) 298.8 (147.0) 195.0 (82.6) n/a 
Disease duration (months) 42.8 (44.2) 52.9 (46.7) 31.9 (44.4) n/a 
% Hypertension 50 50 42.9 10 
% Hypercholesterolemia 50 50 71.4 20 
% past smokers 50 62.5 57.1 30 
% present smokers 50 37.5 42.9 0 
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Table 2. Pearson partial correlations (controlled for the influence of age) between disease 
severity (ABPI), walking endurance (ICD and ACD), and gastrocnemius architectural 
parameters. Values in bold font indicate those reaching significance (P ≤ .05), and values in 
italics indicate those demonstrating trends towards significance (P ≤ .10).  
Gastrocnemius 
architecture 
GL fascicle : 
tendon length 
GM fascicle : 
tendon length 
GL fascicle 
: muscle 
length 
GM fascicle : 
muscle 
length 
ABPI 
Correlation -0.789 -0.828 -0.451 -0.267 
Significance 0.001 <0.001 0.106 0.357 
ICD 
Correlation -0.547 -0.487 -0.312 -0.252 
Significance 0.043 0.081 0.277 0.385 
ACD 
Correlation -0.436 -0.345 -0.290 -0.353 
Significance 0.120 0.228 0.315 0.216 
Gastrocnemii 
architecture 
GL pennation GM pennation 
ABPI 
Correlation 0.188 -.332 
Significance 0.503 .226 
ICD 
Correlation -0.310 -0.807 
Significance 0.261 <0.001 
ACD 
Correlation -0.566 -0.803 
Significance 0.028 <0.001 
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Table 3. Pearson partial correlations (controlled for the influence of age) between disease 
severity (ABPI), walking endurance (ICD and ACD), and Achilles tendon properties. Values 
in bold font indicate those reaching significance (P ≤ .05) and values in italics indicate those 
demonstrating trends towards significance (P ≤ .10).  
Achilles tendon properties 
Tendon 
length 
Tendon 
force 
Elongation 
at maximal 
tendon force 
Stiffness at 
maximal 
tendon force 
ABPI 
Correlation 0.728 0.052 -0.061 0.166 
Significance 0.003 0.854 0.836 0.570 
ICD 
Correlation 0.365 -0.205 -0.110 -0.141 
Significance 0.199 0.463 0.709 0.630 
ACD 
Correlation 0.262 0.224 -0.124 0.165 
Significance 0.366 0.423 0.672 0.573 
Achilles tendon properties 
Young 
modulus at 
maximal 
tendon force 
Peak strain 
Mechanical 
Hysteresis 
ABPI 
Correlation 0.247 -0.490 -0.740 
Significance 0.395 0.075 0.006 
ICD 
Correlation -0.146 -0.261 -0.598 
Significance 0.619 0.367 0.040 
ACD 
Correlation 0.115 -0.219 -0.277 
Significance 0.696 0.453 0.384 
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Table 4. Group mean (SD) musculotendinous length and size parameters.  
 Low ABPI High ABPI 
Asymptomatic-
limb 
Control 
Tibia length (cm) 40.5 (2.4) 41.6 (1.3)A 39.5 (2.5) 38.9 (3.2) 
MTU length (cm) 45.5 (3.7)C 45.8 (1.1)C 43.0 (3.7) 41.6 (4.3) 
Achilles tendon length (cm) 22.3 (3.0) 24.2 (1.1)C,A 21.5 (2.7) 20.6 (2.5) 
Achilles tendon CSA (cm
2
) 89.6 (13.1) 98.5 (23.9) 82.5 (19.5) 85.1 (12.4) 
Lateral Gastrocnemius     
Muscle length (cm) 22.4 (1.2) 21.3 (0.8) 21.6 (1.8) 20.4 (2.5) 
Fascicle length (cm) 4.98 (0.78) 4.77 (0.38) 4.54 (0.50) 4.60 (0.64) 
Fascicle length : Muscle 
length 
0.22 (0.03) 0.22 (0.02) 0.21 (0.02) 0.23 (0.04) 
Fascicle length : Tendon 
length 
0.23 (0.05) 0.20 (0.02)C 0.21 (0.02) 0.22 (0.03) 
Thickness (cm) 1.26 (0.23) 1.29 (0.20) 1.24 (0.24) 1.17 (0.21) 
Pennation (°) 15.2 (2.0) 16.7 (2.8) 16.9 (2.8) 14.8 (1.8) 
Medial Gastrocnemius     
Muscle length (cm) 23.4 (2.6) 22.0 (1.9) 21.3 (2.5) 21.4 (2.5) 
Fascicle length (cm) 4.34 (0.59)C 4.09 (0.29) 4.10 (0.34) 3.65 (0.45) 
Fascicle length : Muscle 
length 
0.19 (0.03) 0.19 (0.02) 0.19 (0.03) 0.17 (0.02) 
Fascicle length : Tendon 
length 
0.20 (0.03)H 0.17 (0.01) 0.19 (0.03) 0.18 (0.03) 
Thickness (cm) 1.77 (0.33) 1.68 (0.31) 1.73 (0.17) 1.62 (0.20) 
Pennation (°) 27.5 (4.5) 26.4 (3.8) 27.9 (4.0) 29.4 (3.8) 
Values in bold font indicate those reaching significance (P ≤ .05), and values in italics 
indicate those demonstrating trends towards significance (P ≤ .10). L: vs low ABPI group 
(High disease severity); H: vs high ABPI group (low disease severity); A:  vs asymptomatic-
limb group; C: vs control group  
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Table 5. Group mean (SD) measures of MVC, Achilles tendon tensile properties, and 
measures of elastic energy.  
 Low ABPI High ABPI 
Asymptomatic-
limb 
Control 
MVC (Nm) 116.4 (29.0) 100.6 (27.2) 102.2 (33.5) 114.4 (28.5) 
GS moment (Nm) 73.6 (20.6) 64.4 (22.6) 63.6 (20.8) 65.2 (14.6) 
Moment arm (cm) 3.47 (0.73) 3.40 (0.48) 3.59 (0.67) 3.24 (0.58) 
Tendon force (N) 2150.3 (591.0) 1947.4 (827.9) 1834.6 (744.9) 2089.6 (630.7) 
Tendon elongation (mm) 18.4 (3.2) 18.7 (2.2)
 
 18.2 (4.5) 15.3 (3.0) 
Stiffness (N/mm
2
) 139.8 (49.9) 129.5 (51.0) 109.4 (37.2)C 184.3 (65.6) 
Young’s modulus (GPa) 0.33 (0.09)C 0.30 (0.09)C 0.30 (0.12)C 0.48 (0.22) 
Tendon strain (%) 8.6 (1.6) 7.8 (1.2) 8.6 (2.2) 7.5 (1.1) 
Tendon stress (MPa) 24.1 (5.8) 19.6 (5.7) 23.2 (10.5) 24.7 (8.3) 
Energy utilisation     
Energy stored (kJ) 20.4 (5.6) 16.8 (9.7) 16.4 (11.4) 13.0 (5.7) 
Energy released (kJ) 16.2 (4.3) 14.5 (7.4) 12.7 (7.6) 11.3 (5.0) 
Mechanical hysteresis (%) 20.1 (5.7)C,H 12.4 (4.0) 17.2 (9.7) 13.2 (4.7) 
Values in bold font indicate those reaching significance (P ≤ .05), and values in italics 
indicate those demonstrating trends towards significance (P ≤ .10).  L: vs low ABPI group 
(High disease severity); H: vs high ABPI group (low disease severity); A: vs asymptomatic-
limb group; C: vs control group  
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Table 6. Backward step-wise regression between architectural parameters, tendon properties, 
and disease severity (ABPI) and walking endurance (ICD). Prediction equations are depicted 
for the model that explains the highest portion of variance (highest adjusted R
2
) and the most 
efficient model (fewest parameters).  
ICD R R
2
 Adjusted R
2
 P-value 
Model 1 0.918 0.843 0.371 0.345 
Model 2 0.918 0.843 0.528 0.179 
Model 3 0.918 0.842 0.621 0.080 
Model 4 0.908 0.825 0.649 0.041 
Model 5 0.891 0.795 0.648 0.023 
Model 6 0.842 0.710 0.565 0.027 
Model 7 0.820 0.672 0.563 0.015 
Prediction for Model 4 = 483.5 - (4.489*Hysteresis) + (0.027*Tendon Force) - 
(0.269*Tendon stiffness) + (4.044*GL pennation) - (11.401*GM pennation) - 
(136.36*ABPI) 
Prediction for Model 7 = 506.690 – (4.935*Hysteresis) – (9.054*GM 
pennation) – (126.544*ABPI) 
Model 1: ABPI, GM pennation, hysteresis, tendon stiffness, tendon force, GL pennation, GM 
fascicle : tendon length, GL fascicle : tendon length, strain 
Model 2: ABPI, GM pennation, hysteresis, tendon stiffness, tendon force, GL pennation, GM 
fascicle : tendon length, GL fascicle : tendon length  
Model 3: ABPI, GM pennation, hysteresis, tendon stiffness, tendon force, GL pennation, GM 
fascicle : tendon length  
Model 4: ABPI, GM pennation, hysteresis, tendon stiffness, tendon force, GL pennation  
Model 5: ABPI, GM pennation, hysteresis, tendon stiffness, tendon force  
Model 6: ABPI, GM pennation, hysteresis, tendon stiffness 
Model 7: ABPI, GM pennation, hysteresis  
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Table 7. Backward step-wise regression between architectural parameters, tendon properties, 
and disease severity (ABPI) and walking endurance (ACD). Prediction equations are depicted 
for the model that explains the highest portion of variance (highest adjusted R
2
) and the most 
efficient model (fewest parameters). 
ACD R R
2
 Adjusted R
2
 P-value 
Model 1 0.892 0.796 0.184 0.460 
Model 2 0.892 0.796 0.387 0.271 
Model 3 0.890 0.793 0.499 0.145 
Model 4 0.887 0.787 0.574 0.069 
Model 5 0.873 0.762 0.593 0.037 
Model 6 0.839 0.704 0.556 0.029 
Model 7 0.798 0.637 0.516 0.023 
Model 8 0.765 0.585 0.502 0.012 
Model 9 0.699 0.489 0.442 0.008 
Prediction for Model 5 = 1322.244 - (15.515*Hysteresis) + (0.099*Tendon 
Force) - (14.474*GL pennation) - (22.324*GM pennation) - (294.257*ABPI) 
Prediction for Model 9 = 934.509 – (-23.988*GM pennation) 
Model 1: GM pennation, tendon force, hysteresis, ABPI, GL pennation, tendon stiffness, 
strain, GM fascicle : tendon length, GL fascicle : tendon length  
Model 2: GM pennation, tendon force, hysteresis, ABPI, GL pennation, tendon stiffness, 
strain, GM fascicle : tendon length 
Model 3: GM pennation, tendon force, hysteresis, ABPI, GL pennation, tendon stiffness, 
strain 
Model 4: GM pennation, tendon force, hysteresis, ABPI, GL pennation, tendon stiffness 
Model 5: GM pennation, tendon force, hysteresis, ABPI, GL pennation 
Model 6: GM pennation, tendon force, hysteresis, ABPI 
Model 7: GM pennation, tendon force, hysteresis  
Model 8: GM pennation, tendon force 
Model 9: GM pennation 
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Figure 1.  Correlations between disease severity (ABPI) and GL and GM fascicle : tendon length ratio (a and 
b respectively) and tendon mechanical hysteresis (c). Control and asymptomatic-limb groups are shown for 
comparison and are not included in correlation analysis  
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